Welcome to our dedicated page for Veracyte news (Ticker: VCYT), a resource for investors and traders seeking the latest updates and insights on Veracyte stock.
Veracyte, Inc. (Nasdaq: VCYT) is a global cancer diagnostics and genomic testing company whose news flow centers on clinical evidence, test performance, and financial results. The company describes its mission as transforming cancer care by empowering clinicians with high-value insights at key decision points in diagnosis and treatment. Its Veracyte Diagnostics Platform underpins tests such as Decipher Prostate, Afirma GSC, Prosigna, Decipher Bladder, and the Percepta Nasal Swab test, along with research tools like Afirma GRID and Decipher GRID.
On this page, readers can follow Veracyte news related to quarterly and annual financial results, including revenue and testing volume updates the company announces in earnings press releases and accompanying conference calls. Veracyte’s communications also highlight non-GAAP measures such as adjusted EBITDA and adjusted EBITDA margin, along with explanations of how these metrics are used internally and how they differ from GAAP figures.
Another major category of news involves clinical and scientific developments. Veracyte regularly reports on studies and abstracts that use its Afirma GRID and Decipher GRID platforms to develop and evaluate molecular signatures in thyroid and prostate cancer. Examples include publications on Afirma GRID-derived signatures to differentiate thyroid cancer risk groups and prospective validation data for biomarkers such as the PAM50 molecular signature in recurrent prostate cancer.
Investors and clinicians can also find announcements about Veracyte’s participation in healthcare and investor conferences, where management presents updates on the company’s diagnostics portfolio, research programs, and financial outlook. For ongoing insight into how Veracyte’s genomic tests and research tools are being used in practice and studied in trials, this news feed aggregates the company’s press releases and related updates in one place.
Veracyte, Inc (Nasdaq: VCYT) will release its full financial results for Q4 and the full year 2020 post-market on February 17. A conference call will follow at 4:30 p.m. ET, where management will discuss financial results and provide a business update. Participants can join via the toll-free U.S./Canada dial-in at (855) 541-0980 or international number (970) 315-0440, using Conference I.D. 7487201. Veracyte leverages genomic diagnostics to enhance patient care and is expanding its test offerings in cancer and other diseases.
Veracyte, Inc. (Nasdaq: VCYT) has completed its public offering of 8,547,297 shares of common stock at a price of $74.00 per share. The offering raised approximately $593.8 million in net proceeds after accounting for underwriting discounts and expenses. This included 1,114,864 shares sold through the underwriters’ full exercise of their option to purchase additional shares. Goldman Sachs & Co. and SVB Leerink served as joint lead book-running managers, with several other firms as co-managers. The offering was conducted under a prior effective shelf registration.
Veracyte, Inc. (VCYT) has priced an underwritten public offering of 7,432,433 shares of common stock at $74.00 per share, anticipating gross proceeds of approximately $550 million. This offering was increased from a prior estimate of $400 million. The funds will primarily support the acquisition of Decipher Biosciences, Inc. and for general corporate purposes. The offering is expected to close on or around February 9, 2021, pending standard conditions. The underwriters have a 30-day option for an additional 1,114,864 shares.
Veracyte, Inc. (Nasdaq: VCYT) has launched an underwritten public offering to sell $400 million in common stock, with an option for underwriters to purchase an additional $60 million. Proceeds will primarily fund the acquisition of Decipher Biosciences, Inc., alongside working capital and general corporate purposes. The offering is backed by Goldman Sachs & Co. LLC and SVB Leerink LLC as lead managers. The shares will be issued under an effective shelf registration statement filed with the SEC.
Veracyte (Nasdaq: VCYT) has announced its acquisition of Decipher Biosciences, a leader in precision oncology focused on urologic cancers, for $600 million. This deal, comprising $250 million in cash and up to $350 million in stock, aims to enhance Veracyte's genomic testing capabilities across seven prevalent cancers in the U.S. Decipher's revenue grew over 130% in 2020 to approximately $39-$40 million. The combined entity expects annualized revenue of about $186 million and an expanded addressable market from $10 billion to $12 billion. Completion is anticipated by May 2021, pending regulatory approval.
Veracyte, Inc. (Nasdaq: VCYT) announced preliminary results for Q4 and FY 2020, projecting total revenue between $34.0 million and $35.0 million for the fourth quarter, and between $117.0 million and $118.0 million for the full year, reflecting a 16% increase in Q4 revenue year-over-year. Testing volume also rose by 14% compared to 2019. The company expects cash equivalents of $345.0 million to $350.0 million as of year-end. CEO Bonnie Anderson highlighted the team's performance and robust pipeline as key to future growth.
Veracyte, Inc (Nasdaq: VCYT) announced that its CEO Bonnie Anderson will present at the 23rd Annual Needham Virtual Growth Conference on January 13, 2021, at 4:15 p.m. ET. A live audio webcast of the presentation will be accessible via the company’s website, with a replay available for 90 days thereafter. Veracyte is a global genomic diagnostics company focused on improving patient care through advanced genomic testing for diseases such as cancer.
Bayer and Veracyte are collaborating to enhance the Precision Oncology Patient Identification Program for thyroid cancer. This initiative will utilize Veracyte's Afirma Xpression Atlas to detect genomic drivers, including NTRK gene fusions, in patients with advanced or radioactive iodine refractory (RAIR) thyroid cancer. The program will provide Afirma XA testing at no cost for eligible patients, supporting informed treatment decisions. Launched in Q1 next year, it aims to help patients with actionable alterations access targeted therapies, impacting approximately 53,000 annual thyroid cancer diagnoses in the U.S.
Summary not available.
Veracyte, Inc. (Nasdaq: VCYT) has revealed preliminary performance data for its noninvasive nasal swab test aimed at early lung cancer detection and the Percepta Genomic Atlas for treatment decisions. Scheduled for launch in late 2021, these tests leverage genomic profiling to cater to patient needs. Initial data indicated that 44-60% of malignant nodules were correctly classified as high-risk, with high specificity (90-91%). Additionally, the Percepta Genomic Atlas demonstrated over 95% accuracy in detecting gene variants in lung cancer. Veracyte continues its commitment to enhancing lung cancer diagnostics.